152 related articles for article (PubMed ID: 17075387)
1. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.
Follmann D; Duerr A; Tabet S; Gilbert P; Moodie Z; Fast P; Cardinali M; Self S
J Acquir Immune Defic Syndr; 2007 Jan; 44(1):49-60. PubMed ID: 17075387
[TBL] [Abstract][Full Text] [Related]
2. On the analysis of viral load endpoints in HIV vaccine trials.
Hudgens MG; Hoering A; Self SG
Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
[TBL] [Abstract][Full Text] [Related]
3. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
Gilbert PB; DeGruttola VG; Hudgens MG; Self SG; Hammer SM; Corey L
J Infect Dis; 2003 Jul; 188(2):179-93. PubMed ID: 12854072
[TBL] [Abstract][Full Text] [Related]
4. Considerations regarding efficacy endpoints in HIV vaccine trials: executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise.
Fruth U
Vaccine; 2009 Mar; 27(14):1989-96. PubMed ID: 19146900
[TBL] [Abstract][Full Text] [Related]
5. Use of predictive markers of HIV disease progression in vaccine trials.
Gurunathan S; Habib RE; Baglyos L; Meric C; Plotkin S; Dodet B; Corey L; Tartaglia J
Vaccine; 2009 Mar; 27(14):1997-2015. PubMed ID: 19200450
[TBL] [Abstract][Full Text] [Related]
6. On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.
Wick WD; Gilbert PB; Self SG
PLoS Comput Biol; 2006 Jun; 2(6):e64. PubMed ID: 16789816
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
Gilbert PB; Bosch RJ; Hudgens MG
Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
[TBL] [Abstract][Full Text] [Related]
8. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
[TBL] [Abstract][Full Text] [Related]
9. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
Adis International Ltd
Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
[TBL] [Abstract][Full Text] [Related]
10. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
[TBL] [Abstract][Full Text] [Related]
11. Some statistical issues in the design of HIV-1 vaccine and treatment trials.
Gilbert PB
Stat Methods Med Res; 2000 Jun; 9(3):207-29. PubMed ID: 11084705
[TBL] [Abstract][Full Text] [Related]
12. HIV/AIDS Vaccines: 2018.
Robinson HL
Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
[TBL] [Abstract][Full Text] [Related]
13. Innate immunity in HIV infection and implications for vaccine design: a summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25-26, 2010.
Bansal GP; Leitner WW
Vaccine; 2010 Dec; 28(52):8229-35. PubMed ID: 21073990
[TBL] [Abstract][Full Text] [Related]
14. A case for preART-adjusted endpoints in HIV therapeutic vaccine trials.
Huang Y; Zhang L; Jolliffe D; Hovden AO; Ökvist M; Pantaleo G; Sommerfelt MA
Vaccine; 2016 Mar; 34(10):1282-8. PubMed ID: 26826543
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.
Graziani GM; Angel JB
J Int AIDS Soc; 2015; 18(1):20497. PubMed ID: 26561337
[TBL] [Abstract][Full Text] [Related]
16. HIV vaccines in infants and children.
Lambert JS
Paediatr Drugs; 2005; 7(5):267-76. PubMed ID: 16220994
[TBL] [Abstract][Full Text] [Related]
17. Use of placebos in Phase 1 preventive HIV vaccine clinical trials.
Huang Y; Karuna ST; Janes H; Frahm N; Nason M; Edlefsen PT; Kublin JG; Corey L; McElrath MJ; Gilbert PB
Vaccine; 2015 Feb; 33(6):749-52. PubMed ID: 25454855
[TBL] [Abstract][Full Text] [Related]
18. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary.
Rida W; Fast P; Hoff R; Fleming T
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):195-203. PubMed ID: 9390572
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert.
Kim HN; Tabet SR; Corey L; Celum CL
Vaccine; 2006 Jan; 24(4):532-9. PubMed ID: 16242816
[TBL] [Abstract][Full Text] [Related]
20. Is the current use of 'positivity' thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?
Richert L; Thiebaut R;
AIDS; 2013 May; 27(8):1362-5. PubMed ID: 23759712
[No Abstract] [Full Text] [Related]
[Next] [New Search]
